Clinical Roundup Study confirms AI outperforms conventional methods for prostate cancer ECE September 06, 2024Vol.50 No.33
Drugs & Targets FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC September 06, 2024Vol.50 No.33
Drugs & Targets FDA accepts Bristol Myers Squibb’s sBLA for Opdivo + Yervoy in unresectable HCC September 06, 2024Vol.50 No.33
Drugs & Targets FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC September 06, 2024Vol.50 No.33
Drugs & Targets NCCN adds Lymphir to Clinical Practice Guidelines in Oncology September 06, 2024Vol.50 No.33
Drugs & Targets EC approves Padcev + Keytruda for advanced urothelial cancer September 06, 2024Vol.50 No.33
Drugs & Targets EC approves Lynparza + Imfinzi for pMMR endometrial cancer September 06, 2024Vol.50 No.33
Drugs & Targets EC grants conditional marketing authorization for Tepkinly for r/r FL September 06, 2024Vol.50 No.33
